The Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization that promotes high-quality, equitable patient care and fosters the discovery and clinical translation of important new therapies that enhance the practice of global oncology as well as supports the prevention and treatment of infectious diseases that impact cancer patients and others with weakened immune systems, thus helping protect the vulnerable from life-threatening infections. STO bridges a translational gap between drug discovery and approved drug delivery with a portfolio of educational activities for physicians and other members of the healthcare team. STO’s decades-long commitment to translational research and education includes fellowships in both cancer and infectious diseases. The latter has become a critical STO commitment during the COVID-19 pandemic from the global genesis to worldwide distribution of new vaccines and improved therapeutics. STO is committed to diversity, inclusivity, and equity throughout its programs.